Sophia Zarubina

Sophia Zarubina is a Scientific Analyst at RBV Capital, a dedicated life sciences venture capital fund. RBV Capital was founded in 2014 (associated with founders Alexey Konov and Robert Karl and registered in Zug, Switzerland) and invests in pharmaceuticals, biologics, digital healthcare products, and medical devices with global commercial potential. In her scientific-analyst role she supports the fund's technical due diligence — the scientific evaluation of biomedical and biotech assets that a life sciences fund relies on to underwrite deals.

Her background is rooted in academic biochemistry rather than finance. Zarubina is a PhD-track researcher in the Department of Chemical Enzymology, Faculty of Chemistry, at Lomonosov Moscow State University (MSU), one of Russia's leading research institutions. Her research group also worked through Innovations and High Technologies MSU Ltd, a university-affiliated commercialization entity.

Her published work centers on enzyme engineering and biocatalysis for pharmaceutical manufacturing. She was lead author on a computational study modeling the 3D structure of alpha-amino acid ester hydrolase from *Xanthomonas rubrilineans* — an enzyme relevant to producing semi-synthetic β-lactam antibiotics such as ampicillin and amoxicillin (PMC3890990) — and has co-authored work on D-amino acid oxidase mutants for cephalosporin C bioconversion and on the stability and coenzyme specificity of bacterial formate dehydrogenases. Her listed research interests include homology modeling, molecular modeling, protein modeling, and molecular dynamics. This deep wet-lab and computational-biochemistry expertise is directly applicable to assessing the science behind early-stage therapeutics.

• Invests within RBV Capital's mandate: life sciences and biomedicine — pharmaceuticals, biologics, digital healthcare, and medical devices that answer unmet medical and market needs with global potential.
• The fund has backed companies from seed through later rounds; recent activity skewed to seed-stage biomedical projects (e.g., PanDx/Pandica, a ~$1.42M seed in 2020).
• Emphasis on scientifically differentiated, IP-driven assets — consistent with a scientific-analyst function focused on validating the underlying biology and technology.
• Because the fund completed its investment cycle in 2020, it is now managing and divesting existing holdings rather than actively deploying into new companies.